CompanyALVO ALVOWNasdaqLuxembourg, N4

Alvotech

Alvotech develops biosimilars targeting autoimmune disorders, eye disorders, and cancer.

SEC EDGAR ClinicalTrials.gov alvotech.com

8-KSep 3Latest SEC filing, period to Sep 3

Aug 31Latest story

August 2026

FDA accepts BLA for Alvotech's AVT80, a subcutaneous Entyvio biosimilar candidate

Aug 31PartnershipAlvotech vedolizumab

Alvotech signs licensing deal with Lotus Pharmaceutical for two biosimilars

Aug 21PartnershipAlvotech

July 2026

Alvotech secures $75 million additional term loan facility from GoldenTree

Jul 1FinancingAlvotech